Cwm LLC Has $155,000 Position in Royalty Pharma plc (NASDAQ:RPRX)

Cwm LLC lessened its position in Royalty Pharma plc (NASDAQ:RPRX) by 22.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,473 shares of the biopharmaceutical company’s stock after selling 1,590 shares during the quarter. Cwm LLC’s holdings in Royalty Pharma were worth $155,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Inspire Investing LLC grew its position in shares of Royalty Pharma by 175.1% in the 1st quarter. Inspire Investing LLC now owns 43,524 shares of the biopharmaceutical company’s stock valued at $1,322,000 after acquiring an additional 27,701 shares during the period. New Century Financial Group LLC acquired a new position in Royalty Pharma during the first quarter worth approximately $1,091,000. Swedbank AB raised its stake in Royalty Pharma by 30.6% in the second quarter. Swedbank AB now owns 10,813,470 shares of the biopharmaceutical company’s stock valued at $285,151,000 after buying an additional 2,533,570 shares during the period. Canada Pension Plan Investment Board lifted its position in shares of Royalty Pharma by 5.2% in the first quarter. Canada Pension Plan Investment Board now owns 923,639 shares of the biopharmaceutical company’s stock valued at $28,051,000 after buying an additional 45,839 shares during the last quarter. Finally, Tidal Investments LLC boosted its stake in shares of Royalty Pharma by 28.2% during the 1st quarter. Tidal Investments LLC now owns 90,149 shares of the biopharmaceutical company’s stock worth $2,740,000 after acquiring an additional 19,834 shares during the period. Institutional investors own 54.35% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on RPRX shares. Morgan Stanley lifted their target price on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, September 17th. Finally, The Goldman Sachs Group increased their target price on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $42.00.

Royalty Pharma Stock Down 0.0 %

RPRX stock opened at $27.36 on Thursday. The stock’s 50 day moving average is $28.02 and its 200-day moving average is $27.65. Royalty Pharma plc has a twelve month low of $25.20 and a twelve month high of $31.66. The firm has a market capitalization of $16.24 billion, a PE ratio of 24.21, a P/E/G ratio of 4.12 and a beta of 0.46. The company has a quick ratio of 9.35, a current ratio of 9.35 and a debt-to-equity ratio of 0.78.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. The business had revenue of $537.00 million for the quarter, compared to analyst estimates of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same period last year, the company posted $0.85 earnings per share. Sell-side analysts expect that Royalty Pharma plc will post 4.05 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a $0.21 dividend. The ex-dividend date is Friday, November 15th. This represents a $0.84 annualized dividend and a dividend yield of 3.07%. Royalty Pharma’s payout ratio is presently 74.34%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.